# Aspect Biosystems

> Aspect Biosystems is a Vancouver, British Columbia biotechnology company developing Bioprinted Tissue Therapeutics — implantable, allogeneic living tissues designed to replace, repair, or supplement biological function in the body. It operates a full-stack tissue therapeutic platform combining AI-powered microfluidic bioprinting, computational tissue design, therapeutic and hypoimmune-engineered cells, and advanced biomaterials, with a pipeline targeting metabolic and endocrine disease.

Generated by the API Evangelist enrichment pipeline on 2026-08-02 from the company's public website. The provider does not publish an llms.txt of its own (https://aspectbiosystems.com/llms.txt returned 404 on 2026-08-02).

**No public API.** Aspect Biosystems is a private, pre-commercial therapeutics developer. As of 2026-08-02 it publishes no developer portal, no API documentation, no SDKs, no OpenAPI/AsyncAPI/GraphQL contract, no MCP server, and no A2A agent card. Its full sitemap contains only corporate, scientific-program, careers, news, and legal pages. Do not attempt to call an Aspect Biosystems API — none is published.

## Company

- [Aspect Biosystems](https://aspectbiosystems.com/): Company homepage.
- [Our Story / About](https://aspectbiosystems.com/about): Company background, values, and leadership team, including founder and CEO Tamer Mohamed.
- [Contact](https://aspectbiosystems.com/contact): 2131 Manitoba Street, Vancouver, BC, Canada V5Y 0N7. +1 604 263 0502. Media inquiries: media@aspectbiosystems.com.
- [Careers](https://aspectbiosystems.com/careers): Open roles, posted via the Greenhouse board at https://job-boards.greenhouse.io/aspectbiosystems.
- [Privacy Policy](https://aspectbiosystems.com/privacy-policy): How the company collects, uses, discloses, and manages personal information.

## Science and platform

- [Technology Platform](https://aspectbiosystems.com/technology): The full-stack tissue therapeutic platform — computational tissue design, cell and biomaterial processing, manufacturing of tissue therapeutics, and implantation.
- [Therapeutic Programs](https://aspectbiosystems.com/programs): Pipeline of bioprinted tissue therapeutics for metabolic and endocrine disease, led by type 1 diabetes and rare endocrine disorders.
- [Partnerships](https://aspectbiosystems.com/partnerships): Pharma and biotech collaborations, including Novo Nordisk.

## News

- [News + Resources](https://aspectbiosystems.com/news-resources): Dated press releases, media coverage, event listings, and partnership announcements.
- [Series B financing](https://aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics): US$115M Series B to advance bioprinted tissue therapeutics.
- [Novo Nordisk partnership](https://aspectbiosystems.com/news-resources/novo-nordisk-partnership-to-develop-bioprinted-tissue-therapeutics-for-diabetes-and-obesity): Partnership to develop bioprinted tissue therapeutics for diabetes and obesity.
- [Government of Canada and British Columbia partnership](https://aspectbiosystems.com/news-resources/aspect-biosystems-announces-200-million-partnership-with-the-governments-of-canada-and-british-columbia-to-advance-development-of-bioprinted-tissue-therapeutics): CA$200M partnership to advance development of bioprinted tissue therapeutics.

## Code and social

- [GitHub organization](https://github.com/aspectbiosystems): Aspect Biosystems Ltd. Five public repositories, all forks of third-party tooling (AvalonEdit, jetson-utils, opencvsharp, opencv_v4l2, a Tecan syringe-pump control fork). No first-party SDK, client library, or API implementation is published.
- [LinkedIn](https://ca.linkedin.com/company/aspect-biosystems)
- [YouTube](https://www.youtube.com/channel/UC2VA_o9ifVNxAEVoI73j8tA)

## Optional

- [API Evangelist profile](https://apis.io/provider/aspect-biosystems/): This company's entry in the APIs.io catalog.
- [Hiive secondary-market listing](https://www.hiive.com/securities/aspect-biosystems-stock): Private-market share listing that surfaced this company into the harvest backlog.